Position in NVS
as of Mar 31, 2026
· filed May 12, 2026
Position Value
$82,150,935
New position
Shares Held
537,813
first reported quarter
Ownership
0.028%
of shares outstanding
% of Portfolio
0.13%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2026
1 quarter on record
Voting authority
Sole 98.86726427215407.ToString("F0")%
Shared 0.ToString("F0")%
None 1.1327357278459242.ToString("F0")%
Position in Drug Manufacturers - General
Healthcare · as of Mar 31, 2026CIBC Bancorp USA Inc. holds $3,074,306,330 across 14 Drug Manufacturers - General names. NVS ranks #7 (2.7% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | AZN |
Astrazeneca PLC
|
4,595,892 | $906,401,819 | |
| 2 | LLY |
ELI LILLY & Co
|
904,660 | $832,079,127 | |
| 3 | JNJ |
Johnson & Johnson
|
1,673,159 | $408,986,985 | |
| 4 | ABBV |
AbbVie Inc.
|
1,726,928 | $375,589,569 | |
| 5 | AMGN |
Amgen Inc
|
545,461 | $191,920,452 | |
| 6 | MRK |
Merck & Co., Inc.
|
1,047,115 | $125,957,462 | |
| 7 | NVS |
Novartis AG
This page
|
537,813 | $82,150,935 | |
| 8 | PFE |
Pfizer Inc
|
1,770,963 | $49,728,639 |
All Filings in NVS
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $82,150,935 | 537,813 | Shares | Defined | 2026-05-12 | |
| No filing history on record for this holder in this stock. | ||||||